Bristol Myers: positive phase 2 data in lymphoma
(CercleFinance.com) - Bristol Myers Squibb announces that the TRANSCEND FL trial evaluating Breyanzi in adults with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma has met its primary endpoint in the marginal zone lymphoma cohort.
This Phase 2 trial demonstrated a statistically and clinically significant overall response rate (ORR). It also met its key secondary endpoint of complete response rate (CRR), and no new safety signals were observed.
With this data, Breyanzi demonstrates its efficacy and manageable safety in a fifth cancer type, the largest number of all CAR-T cell therapies directed against CD19, the pharmaceutical company says.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
This Phase 2 trial demonstrated a statistically and clinically significant overall response rate (ORR). It also met its key secondary endpoint of complete response rate (CRR), and no new safety signals were observed.
With this data, Breyanzi demonstrates its efficacy and manageable safety in a fifth cancer type, the largest number of all CAR-T cell therapies directed against CD19, the pharmaceutical company says.
Copyright (c) 2025 CercleFinance.com. All rights reserved.